United Kingdom· GB-APID-29507211000001103

Jakavi 10mg tablets

A ruxolitinib product containing ruxolitinib, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 14 of our 19 countries.

ATC L01EJ01

Checked against NHS dm+d (United Kingdom) on September 13, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ruxolitinibAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Ruxolitinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EJ01 (ruxolitinib), each read from that country’s own register.

This record: United Kingdom, from NHS dm+d (United Kingdom)
8 of them publish a price we can compare per daily dose

Search ruxolitinib products by name

Ruxolitinib · ATC L01EJ01

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ruxolitinib costs, country by country.

Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Ruxolitinib · price per daily dose (30 mg)

USD · FX 28 Sept 2026

CH Switzerland$223.34

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)

Active substance: Ruxolitinib
Manufacturer: Novartis Pharmaceuticals UK Ltd
Country: United Kingdom (GB)
ATC code: L01EJ01
ATC class: Ruxolitinib
Defined daily dose: 30 mg, O
Reimbursed: Not published by this register
Source register: NHS dm+d (United Kingdom)
Last checked: September 13, 2026

Packs & prices · 2

gtin
5010678910070
gtin
7613421048242

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

350 interactions on record for ruxolitinib.

Graded by severity as the source publishes them — 92 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check ruxolitinib against other medicines How interaction checks work

Ruxolitinib · interactions on record

350 records

92 severe
199 moderate
59 minor

Most severe, free to view

LonafarnibA16AX20severe
DalteparinB01AB04severe
EnoxaparinB01AB05severe
DanaparoidB01AB09severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ruxolitinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ruxolitinib products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

Austria · Polink, Ruxib
Bulgaria · Руджави, Руксолитиниб Сандоз
Cyprus · Ruxolitinib Sandoz
Czechia · Ruxolitinib Msn, Ruxolitinib Sandoz
Denmark · Ruxolitinib "sandoz", Ruxolitinib Devatis
Estonia · Ruxolitinib Msn
Spain · Ruxolitinib Cipla, Ruxolitinib Vivanta
Finland · Ruxolitinib Orion
France · Ruxolitinib Biogaran, Ruxolitinib Olpha
Greece · Jakulya
Croatia · Ruksolitinib Devatis, Ruksolitinib Msn
Hungary · Ruxolitinib Sandoz
Iceland · Jakavi, Jakulya
Italy · Ruxolitinib Vivanta
Liechtenstein · Jakavi, Opzelura
Lithuania · Ruxolitinib Msn, Ruxolitinib Olpha
Latvia · Ruxolitinib Msn
Malta · Donlize, Ruxolitinib Medichem
Netherlands · Ruxolitinib Accord, Ruxolitinib Advanz Pharma
Norway · Jakavi, Opzelura
Romania · Ruxolitinib Msn
Sweden · Ruxolitinib Devatis, Ruxolitinib Orion

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/af27ce2a-396f-4da5-bf6b-51fa10975818
GET /v1/drugs/af27ce2a-396f-4da5-bf6b-51fa10975818?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "29507211000001103",
  "desc": "Jakavi 10mg tablets (Novartis Pharmaceuticals UK Ltd)",
  "form": "Oral tablet",
  "vpid": "39703411000001109",
  "source": "dmd",
  "vtm_id": "777477007",
  "strength": "10 mg",
  "substance": "Ruxolitinib",
  "ingredient": "Ruxolitinib phosphate",
  "supplier_code": "2920101000001102"
}

API reference MCP server Plans

See everything about ruxolitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console